Oncosting LLC
Publicly observedBaltimore, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Baltimore | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Oncosting LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | DJXQC89K4S79 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Sept 2026Publicly observed
NIH SBIR/STTR award: STING agonist-expressing BCG to enhance bladder cancer therapy
USD 1,030,215.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant20 Jun 2024Publicly observed
NIH SBIR/STTR award: BCG overexpressing a small molecule STING agonist as a vaccine for TB
USD 986,921.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Jun 2024Publicly observed
NIH SBIR/STTR award: BCG overexpressing a small molecule STING agonist as a vaccine for TB
USD 991,112.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.